Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study
- DDP733 reduces esophageal reflux - Waltham, Mass., June 7, 2007 – Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-...Dynogen Reports Positive Results in Phase 1B GERD Study
...double-blind, placebo-controlled Phase 1b trial of ddp733 for gastroesophageal reflux disease (GERD). The st...y was designed to demonstrate proof-of-concept for ddp733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of ddp733 achieved statistical significance over placebo on ...Dynogen Presents Results Of Its Positive Phase 2a IBS-c Study With DDP733
Dynogen Pharmaceuticals, Inc. announced the presentation of positive results from its Phase 2a clinical trial for DDP733 (pumosetrag) as a treatment for irritable ...Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel ...
Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel ...Dynogen to Receive Two Key European Patents for DDP733
Dynogen is also studying DDP733 in a Phase 1b translational medicine clinical ... Preclinical studies of DDP733 established the compound's prokinetic properties ...Press Release: Dynogen Pharmaceuticals Reports Positive Results In ...
Press Release: Dynogen Pharmaceuticals Reports Positive Results In Phase 2 IBS-c ... DDP733 achieved an overall clinical response rate of 54% in patients receiving a ...Dynogen Pharmaceuticals, Inc. Reports Positive Results In Phase 2 IBS-c ...
DDP733 achieved an overall clinical response rate of 54% in patients receiving a ... Preclinical studies of DDP733 established the compound's prokinetic properties ...